Pharmaceutical Anti-Angiogenic Composition Including a MicroRNA-382 Inhibitor
AssigneeKyungpook National University-Academic Cooprtation Foundation
InventorYou Mie Lee
Life of this patent
Estimating the term…
Abstract
The present invention relates to an anti-angiogenic composition, and more particularly, to a pharmaceutical anti-angiogenic composition including a microRNA-382 inhibitor. The inventors of the present invention have confirmed that microRNA-382, the expression of which is elevated in stomach cancer cells in a low oxygen environment, affects the promotion of angiogenesis induced in a low oxygen environment. Therefore, the pharmaceutical composition of the present invention inhibits microRNA-382 and thus inhibits angiogenesis and cell proliferation, and is expected ultimately to be valuably used in the treatment of cancer.
Claims6
A pharmaceutical composition for inhibiting angiogenesis, including a microRNA-382 inhibitor.
A method of treating a cancer by inhibiting proliferation of cancer cells in a subject in need thereof, the method comprising administering to the subject a composition comprising a pharmaceutically effective amount of a microRNA-382 inhibitor.
Dependencies are inferred from the claim text.